WO2014020351A1 - Receptor antagonists - Google Patents

Receptor antagonists Download PDF

Info

Publication number
WO2014020351A1
WO2014020351A1 PCT/GB2013/052070 GB2013052070W WO2014020351A1 WO 2014020351 A1 WO2014020351 A1 WO 2014020351A1 GB 2013052070 W GB2013052070 W GB 2013052070W WO 2014020351 A1 WO2014020351 A1 WO 2014020351A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
carbamimidoylphenyl
benzamide
phenyl
phenylbenzamide
Prior art date
Application number
PCT/GB2013/052070
Other languages
French (fr)
Inventor
Paul Meo
Alison Stewart
Christopher Hobbs
Original Assignee
Proximagen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Limited filed Critical Proximagen Limited
Publication of WO2014020351A1 publication Critical patent/WO2014020351A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/10—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • This invention relates to compounds that are PAR2 receptor antagonists, to compositions containing them, to processes for their preparation, and to their use in medicine, in particular for the treatment of conditions which respond to antagonism of the PAR2 receptor, such as inflammation including intestinal inflammation including ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome, fibrosis, arthritis and inflammatory skin diseases including psoriasis, atopic dermatitis and itch, pain and cancer.
  • inflammation including intestinal inflammation including ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome, fibrosis, arthritis and inflammatory skin diseases including psoriasis, atopic dermatitis and itch, pain and cancer.
  • Protease activated receptors are a family of seven transmembrane domain G- protein-coupled receptors that are activated by cleavage of their extracellular N-terminal domain by proteolytic enzymes. The newly exposed N-terminal sequence acts as a tethered ligand that binds to the extracellular face of the receptor and activates it.
  • PARs Four PARs have been described that are selectively cleaved by different enzymes; PARI, PAR3 and PAR4 are cleaved by thrombin, PAR2 and PAR4 predominantly by trypsin and tryptase and PAR4 also cleaved by cathepsin G.
  • the GI tract and pancreas are particularly exposed to a large array of proteases which can activate PAR2 receptors. Trypsin is released into the lumen of the pancreatic duct and the upper GI tract, for physiological digestive purposes. Other proteases abundant in the GI tract include those derived from enteric bacteria and those generated during disease processes. On mucosal surfaces, a balance between proteolytic activity and the presence of protease inhibitors such as pancreatic secretory trypsin inhibitor (PSTI) is constantly present. PAR2 receptors are expressed throughout the GI tract specifically on mast cells, smooth muscle cells, myenteric neurons and endothelial cells, and on both the apical and basolateral sides of enterocytes (Kong et al, 1997).
  • this receptor may provide a means by which the epithelium "senses" luminal processes.
  • motility and secretion are regulated by neurons of the submucosal and myenteric plexi of the gastrointestinal tract.
  • These neurones express PARI, PAR2 and PAR4.
  • PAR2 is expressed by secretomotor neurons in the submucosal plexus of the small intestine, where brief activation of PAR2 by agonists such as SLIGRL-NH 2 or trypsin results in a prolonged depolarisation that is often accompanied by increased excitability.
  • PAR2 activation is important in the establishment, maintenance, and progression of intestinal inflammation and of fibrosis.
  • Psoriasis is a common skin condition which typically develops as patches ('plaques') of red, scaly skin. People with psoriasis have a faster turnover of skin cells associated with changes in the blood supply of the skin (redness) which causes local inflammation. Psoriasis is not due to an infection and is not infectious, nor is it cancerous.
  • a PAR2 antagonist will be effective in the treatment of inflammatory skin diseases including psoriasis and itch.
  • topical or systemic administration of a PAR2 antagonist would reduce the itch caused by local inflammation in psoriasis, and therefore would constitute a targeted treatment for this unchallenged symptom of psoriasis.
  • a PAR2 antagonist will be effective in the treatment of arthritis due to inflammation in or around the joint.
  • PAR-2 has been implicated in cellular proliferation, invasion and metastasis. There is increasing evidence that PAR2 is an important mediator of tumour progression, with trypsin levels being elevated in gastric, colon, ovarian and lung tumours (Ducroc et al., 2002). In addition PAR-2 is expressed in cancers of the lungs, liver, prostate, thyroid, breast, gastrium, colon, pancreas, gallbladder, melanoma and glioblastoma (see Jahan et al., 2007 and references therein).
  • Tissue factor is a primary component of the clotting cascade which with Factor Vila or Factor Xa can initiate clotting. Cancer patients are frequently in a pro- thrombotic state, apparently partly due to the release of TF containing microparticles (small membranous fragments perhaps released on apoptosis). TF is expressed at high levels in vessel wall fibroblasts but may also be expressed on endothelial and smooth muscle cells (Kasthuri et al., 2009). TF is also heavily implicated in cancer, its expression generally increasing with cancer stage (Kakkar et al., 1995; Kasthuri et al., 2009) and appears to be involved in metastasis (Belting et al., 2005).
  • TF may play a role in forming the fibrinous clot around metastatic cells which serves to protect them from NK cells and to maintain them in the vasculature (Palumbo et al., 2005, 2007).
  • TF/Factor Vila/Factor Xa complexes stimulate breast carcinoma cell migration and invasion through activation of PAR2 (Hjortoe et al., 2004; Morris et al., 2006).
  • activated PAR2 stimulates EGFR activity and thus cellular proliferation (Caruso et al, 2006); Darmoul et al., 2004).
  • PAR2 receptor activation has been shown to be important in inflammatory disorders. Based on in vivo studies in models of inflammatory disorders (Kelso et al, JPET, 2006, 316, 1017-1024, Sevigny, PNAS, 2011, 108, 20, 8491-8496 and Cenac et al, JDR, 2010, 89, 10, 1123-1128) it is expected that antagonism of the PAR2 receptor will be effective in the treatment of inflammatory disorders.
  • Pancreatitis is an inflammatory condition understood to be the result of undesirable trypsin activity within the pancreas.
  • the biological effects of trypsin in the pancreas have been shown to act through PAR2, which is strongly expressed on the luminal surface of acinar and ductal cells (Ceppa et al., 2011).
  • Antagonism of the effects of trypsin at PAR2, within the pancreas, can be expected to be an effective treatment for pancreatitis.'
  • the PAR2 receptor is regarded as a target for intervention in the treatment of the conditions referred to above.
  • This invention makes available compounds which are antagonists of the PAR2 receptor, and their use in indications which respond to the antagonism of the PAR2 receptor such as those mentioned above.
  • the compounds of the invention are antagonists of the PAR2 receptor. Therefore, in another broad aspect the invention provides the use of a compound of the invention in the treatment of, or in the preparation of a composition for treatment of, diseases or conditions responsive to the reduction of PAR2 mediated activity.
  • diseases or conditions which are responsive to the reduction of PAR2 mediated activity include inflammation including intestinal inflammation (such as ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome), fibrosis, arthritis and inflammatory skin diseases (such as psoriasis, atopic dermatitis and itch), pain and cancers including cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma.
  • the compounds with which the invention is concerned may be used for the reduction of PAR2 mediated activity, ex vivo or in vivo.
  • the compounds of the invention may be used in the preparation of a composition for the treatment of diseases or conditions selected from inflammation including intestinal inflammation (such as ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome), fibrosis, arthritis and inflammatory skin diseases (such as psoriasis, atopic dermatitis and itch), pain and cancers including cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma.
  • intestinal inflammation such as ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome
  • fibrosis fibrosis
  • arthritis inflammatory skin diseases
  • pain and cancers including cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma.
  • the invention provides a method for the treatment of the foregoing disease types, which comprises administering to a subject suffering such disease an effective amount of a compound of the invention.
  • composition comprising a compound of the invention together with one or more pharmaceutically acceptable carriers and/or excipients.
  • the compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • the compounds can be administered in a sublingual formulation, for example a buccal formulation.
  • the compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally, by inhalation, intranasally, or by infusion techniques.
  • the compounds may also be administered as suppositories.
  • the compounds may also be administered topically. Thus, the compounds of the invention are administered orally, or by inhalation, topically, or intranasally.
  • the compounds of the invention are administered orally and more preferably, the compounds of the invention are administered as a tablet or capsule.
  • administration of the compounds in a hard gelatine capsule form, or in one of the many sustained release formulations known in the art will often be preferred.
  • the compounds of the invention are administered as a topical treatment.
  • the present invention further provides a pharmaceutical composition containing a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above, and a pharmaceutically acceptable carrier.
  • solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
  • diluents e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch
  • lubricants e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols
  • binding agents e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrroli
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
  • the present invention further provides a pharmaceutical composition containing a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above, and a pharmaceutically acceptable carrier in the form of a capsule or tablet.
  • the compounds of the invention are preferable administered topically.
  • the compounds may be formulated in any form suitable for topical administration including semi-solid, spray, medicated powders, solution, and medicated adhesive systems.
  • the compounds of the invention may be administered as external topicals that are spread, sprayed, or otherwise dispersed on to cutaneous tissues to cover the affected area. Topical drug delivery is especially effective in the fields of psoriasis, itch, and pain management.
  • Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the art. However, it is expected that a typical dose will be in the range from about 0.001 to 50 mg per kg of body weight.
  • salts include base addition, acid addition and ammonium salts.
  • compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like.
  • bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine
  • Those compounds of the invention which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, trifluoroacetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p- toluenesulphonic, benzoic, benzenesulfonic, glutamic, lactic, and mandelic acids and the like.
  • hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like
  • organic acids e.g. with acetic, trifluoroacetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic,
  • Those compounds (I) which have a basic nitrogen can also form quaternary ammonium salts with a pharmaceutically acceptable counter-ion such as chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene- bis sulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like.
  • a pharmaceutically acceptable counter-ion such as chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene- bis sulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like.
  • a pharmaceutically acceptable counter-ion such as chloride, bromide, acetate, formate, p-toluenesulfonate,
  • any reference herein, including the claims herein, to "compounds with which the invention is concerned” or “compounds of the invention” or “the present compounds”, and the like, includes reference to salts, hydrates, and solvates of such compounds.
  • the term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
  • solvent molecules for example, ethanol.
  • 'hydrate' is employed when said solvent is water.
  • Individual compounds of the invention may exist in an amorphous form and /or several polymorphic forms and may be obtained in different crystal habits. Any reference herein, including the claims herein, to "compounds with which the invention is concerned” or “compounds of the invention” or “the present compounds”, and the like, includes reference to the compounds irrespective of amorphous or polymorphic form.
  • Some compounds of the invention, having a nitrogen atom in an aromatic ring, may form N-oxides, and the invention includes compounds of the invention in their N-oxide form.
  • intermediates described herein can also be used as therapeutic agents to treat or more of the diseases or conditions described throughout.
  • the compounds of the invention may be prepared by, or in analogy with, conventional methods.
  • the preparation of intermediates and compounds according to the Examples of the present invention are illustrated as follows.
  • Analytical HPLC was performed on an Agilent 1100 system using a Phenomenex Synergi, RP-Hydro, 150 x 4.6mm, 4um column with a flow rate of 1.5mL per min at 30°C (200-3 OOnm) and a gradient of 5-100% MeCN (+0.085% TFA) in water (+0.1% TFA) over 7min.
  • Mass directed HPLC was performed on a Waters system using a Phenomenex Gemini, CI 8, 100 x 21mm, 5um column with a flow rate of 20mL per min over 14.5min.
  • Flash chromatography was performed on either a CombiFlash Companion system equipped with RediSep silica columns or a Flash Master Personal system equipped with Strata SI- 1 silica gigatubes or in a glass column under gravity.
  • Reverse Phase HPLC was performed on a Gilson system (Gilson 322 pump with Gilson 321 equilibration pump and Gilson 215 autosampler) equipped with Phenomenex Synergi Hydro RP 150 x 10mm, or YMC ODS-A 100/150 x 20mm columns. Microwave irradiations were carried out using a Biotage microwave. Hydrogenations were performed using a Thales H-cube Nano. Reactions were performed at room temperature unless otherwise stated. The compounds were automatically named using ACD 6.0. All compounds were dried in a vacuum oven overnight. Where yields are not included, the intermediates were used crude. Reactions were monitored by TLC, LCMS or HPLC.
  • Benzamide (l.OOg, 8.25mmol) was dissolved in dioxane (20mL), chlorocarbonylsulfenyl chloride (0.70mL, 8.25mmol) was added and the reaction mixture was heated under reflux at 101°C for 6h. The reaction mixture was concentrated in vacuo and the residue was dissolved in m-xylene (30mL). Methyl propiolate (0.84mL, 14.0mmol) was added and the reaction mixture was heated under reflux at 139°C for 24h. The reaction mixture was concentrated in vacuo and the residue was partitioned between DCM (50mL) and water (30mL).
  • Examples 3-29 and 31-52 were prepared similarly to Example 1; see Table 5 below.
  • Examples 57-59 were prepared similarly to Example 1; see Table 6 below.
  • the PAR2 receptor couples through the Gq signaling pathway and results in activation of calcium mobilization.
  • the functional activity of test compounds was routinely tested by measuring the ability of compounds to antagonize PAR2 (trypsin challenge) activity in a dose dependent manner, in Wild type HEK-293 cells, 1321N1 cells transfected with the rat PAR2 receptor and 1321N1 cells transfected with the mouse PAR2 receptor, using a calcium flux Fluorescent Imaging Plate Reader FLIPR assay.
  • test compounds were dissolved in DMSO to a concentration of 50mM and stored in matrix screenmate racks. The required amount of compound was transferred to 96-well compound plates on the day of assay and dose-response measurements were assayed by making 1 :3.16 serial dilutions to produce 10 point curves. Compounds were then diluted in assay buffer to the required final concentration before being transferred to 384-well assay plates ready for use. Top concentrations were adjusted depending on the potency of the compounds with a typical concentration range of 200 uM to 6.3 nM being used.
  • the assay buffer used was HBSS buffer supplemented with 20 mM HEPES, 2.5 mM Probenicid, adjusted to pH7.4. The loading/wash buffers were the same as the assay buffer.
  • Wild type HEK-293 cells were cultured in MEM AQmedia containing Glutamine, supplemented with 10% FBS, 1% (5 ml) Penicillin/Streptomycin and 1% Non Essential Amino Acids.
  • Rat or Mouse PAR2 transfected 1321N1 cells were cultured in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% dialyzed FBS, 1% Penicillin/Streptomycin, 378.5 ug/ml Geneticin G418 sulphate and maintained at 37 °C in a humidified, 5% C02 controlled atmosphere. Sub-cultivations were performed every 2-3 d.
  • DMEM Dulbecco's modified Eagles medium
  • the cells were lifted using 0.25% Trypsin (IX), spun at 1000 rpm for 3 min and re-suspended in medium at 3.3 x 10 5 cells/mL, transferred (30 ⁇ /well) to 384-well black/clear BD plates (SLS # 56663BD) and incubated at 37 °C in a 5% C02/95% air humidified incubator for 16 h.
  • the cells were washed with assay buffer at 37 °C using the Biotek ELx 405, washing 3 times, leaving 20 ul buffer in the well.
  • the cells were loaded with Fluo-4 AM dye (Molecular probes) at 2 uM containing 0.48 ug/mL pluronic acid for 60 min at 37 °C under 5% C02. Following the incubation, cells were washed in assay buffer at 37 °C using the Biotek ELx 405, washing 3 times, leaving 40 ⁇ in each well and incubated for 10 min at 37 °C before use.
  • Fluo-4 AM dye Molecular probes
  • a combined agonist/antagonist protocol was used to measure changes in intracellular calcium concentration.
  • Compound (antagonist) was added to the cell plate using a
  • Fluorometric Imaging Plate Reader (FLIPR) (Molecular Devices, Sunnyvale, CA, USA).
  • Basal fluorescence was recorded every second for 10 sec prior to compound addition (10 uL) and fluorescence recorded every second for 1 min then every 6 sec for a further 1 min.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

N-(4-carbamimidoylphenyl)-amide derivatives having utility in therapy as PAR2 receptor antagonists.

Description

Receptor Antagonists
Introduction
This invention relates to compounds that are PAR2 receptor antagonists, to compositions containing them, to processes for their preparation, and to their use in medicine, in particular for the treatment of conditions which respond to antagonism of the PAR2 receptor, such as inflammation including intestinal inflammation including ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome, fibrosis, arthritis and inflammatory skin diseases including psoriasis, atopic dermatitis and itch, pain and cancer.
Background to the invention
Protease activated receptors (PARs) are a family of seven transmembrane domain G- protein-coupled receptors that are activated by cleavage of their extracellular N-terminal domain by proteolytic enzymes. The newly exposed N-terminal sequence acts as a tethered ligand that binds to the extracellular face of the receptor and activates it. Four PARs have been described that are selectively cleaved by different enzymes; PARI, PAR3 and PAR4 are cleaved by thrombin, PAR2 and PAR4 predominantly by trypsin and tryptase and PAR4 also cleaved by cathepsin G.
PAR-2 in the GI tract
The GI tract and pancreas are particularly exposed to a large array of proteases which can activate PAR2 receptors. Trypsin is released into the lumen of the pancreatic duct and the upper GI tract, for physiological digestive purposes. Other proteases abundant in the GI tract include those derived from enteric bacteria and those generated during disease processes. On mucosal surfaces, a balance between proteolytic activity and the presence of protease inhibitors such as pancreatic secretory trypsin inhibitor (PSTI) is constantly present. PAR2 receptors are expressed throughout the GI tract specifically on mast cells, smooth muscle cells, myenteric neurons and endothelial cells, and on both the apical and basolateral sides of enterocytes (Kong et al, 1997). Since trypsin present in the GI lumen could activate PAR2 on apical surfaces, this receptor may provide a means by which the epithelium "senses" luminal processes. In the gut, motility and secretion are regulated by neurons of the submucosal and myenteric plexi of the gastrointestinal tract. These neurones express PARI, PAR2 and PAR4. PAR2 is expressed by secretomotor neurons in the submucosal plexus of the small intestine, where brief activation of PAR2 by agonists such as SLIGRL-NH2 or trypsin results in a prolonged depolarisation that is often accompanied by increased excitability. Tryptase also induces a transient depolarization and a sustained increase in neuronal excitability (Linden et al., 2001). These observations indicate that PAR2 excites a proportion of myenteric neurons, which may contribute to dysmotility during intestinal inflammation.
A recent report concluded that activation of PAR2 in GI epithelial cells could trigger pro-inflammatory signaling including release of IL-8 via two independent pathways, MEK/ERK and PI3K/Akt. PAR2 would thus be confirmed to be a therapeutic target for treatment of inflammatory diseases of the GI tract (Tanaka et al., 2008). Histological studies in fibrotic intestine from patients with Crohn's disease indicated that (myo)fibroblasts are expanded in number and are the major cell types at sites of fibrosis in all layers of the intestinal wall (Pucilowska et al., 2000). Recent analysis of inflammatory tissues from patients with Crohn's Disease showed PAR2 over-expression in all cell types analyzed, including fibroblasts (Ketabchi et al., 2007). These results are in line with observations showing PAR2 over expression during fibrosis of lung and kidney (Cederqvist et al., 2005; Grandaliano et al., 2003). In these studies, PAR2 was identified as a potentially crucial receptor for the pathogenesis and sustainability of fibrosis. This hypothesis has recently been substantiated by a report linking normal activation of PAR2 by the protease Factor X resulting in tissue regeneration following injury, to the fibrotic response seen following repeated stimulation of this system as a consequence of chronic inflammatory bowel disease (IBD, Borensztajn et al., 2008).
In conclusion, PAR2 activation is important in the establishment, maintenance, and progression of intestinal inflammation and of fibrosis.
Itch associated with psoriasis and atopic dermatitis
Itch in human skin can be induced by both histamine and proteases. The ability of the PAR2 agonist SLIGRL-NH2 to cause scratching behaviour in mice was not antagonised by antihistamine treatment (Shimada et al., 2006). The authors concluded that PAR2 was a histamine independent mediator of itch. Such an interpretation has been strengthened by the identification of the receptor on the terminals of sensory nerve fibres which transduce the itch sensation (Steinhoff et al., 2000). In non-GI tissues such as the skin, "tissue trypsins" are secreted which can activate PAR2 receptors, as can other proteases including tryptase, Factor X, Factor Vila and Tissue Factor (Bunnett, 2006). In patients with atopic dermatitis PAR-2 has also been strongly implicated as a major cause of itch (Steinhoff et al., 2003).
Psoriasis is a common skin condition which typically develops as patches ('plaques') of red, scaly skin. People with psoriasis have a faster turnover of skin cells associated with changes in the blood supply of the skin (redness) which causes local inflammation. Psoriasis is not due to an infection and is not infectious, nor is it cancerous.
Itch in psoriasis is a significant but often unrecognized problem in dermatology. A recent study found that itching was the most frequent complaint (64%) among patients hospitalised for psoriasis, (Sampogna et al., 2004) and several other studies confirm that itch is a principal symptom of psoriasis (Van de Kerkhof et al., 1998, 2000). Interestingly PAR2 receptors are highly expressed in the skin of psoriatic patients (Steinhoff et al., 1999), as are numerous tryptase-positive cells. These are found in the dermis and at the dermal-epidermal border in atopic dermatitis and psoriasis, and occasionally in the epidermis of psoriasis lesions. Tryptase released from such cells activates PAR2 in keratinocytes which may induce local inflammatory changes and thereby contribute to the pathophysiology of atopic dermatitis and psoriasis.
Furthermore it is hypothesised that other types of itch such as neuropathic itch are linked to an activation of PAR2 receptors by proteases (Binder et al, 2008).
For the forgoing reasons it is expected that a PAR2 antagonist will be effective in the treatment of inflammatory skin diseases including psoriasis and itch. In particular, it is expected that topical or systemic administration of a PAR2 antagonist would reduce the itch caused by local inflammation in psoriasis, and therefore would constitute a targeted treatment for this unchallenged symptom of psoriasis. It is also expected that a PAR2 antagonist will be effective in the treatment of arthritis due to inflammation in or around the joint.
Pain The transmission of pain and/or unpleasant sensation is also enhanced by activation of PAR2 receptors as application of activating peptide excites C fibres and sensitises them to heat (Ding-Pfennigdorf et al, 2004). Cancer
PAR-2 has been implicated in cellular proliferation, invasion and metastasis. There is increasing evidence that PAR2 is an important mediator of tumour progression, with trypsin levels being elevated in gastric, colon, ovarian and lung tumours (Ducroc et al., 2002). In addition PAR-2 is expressed in cancers of the lungs, liver, prostate, thyroid, breast, gastrium, colon, pancreas, gallbladder, melanoma and glioblastoma (see Jahan et al., 2007 and references therein).
Tissue factor (TF) is a primary component of the clotting cascade which with Factor Vila or Factor Xa can initiate clotting. Cancer patients are frequently in a pro- thrombotic state, apparently partly due to the release of TF containing microparticles (small membranous fragments perhaps released on apoptosis). TF is expressed at high levels in vessel wall fibroblasts but may also be expressed on endothelial and smooth muscle cells (Kasthuri et al., 2009). TF is also heavily implicated in cancer, its expression generally increasing with cancer stage (Kakkar et al., 1995; Kasthuri et al., 2009) and appears to be involved in metastasis (Belting et al., 2005). Indeed TF may play a role in forming the fibrinous clot around metastatic cells which serves to protect them from NK cells and to maintain them in the vasculature (Palumbo et al., 2005, 2007). TF/Factor Vila/Factor Xa complexes stimulate breast carcinoma cell migration and invasion through activation of PAR2 (Hjortoe et al., 2004; Morris et al., 2006). In addition in other cancers including colon and gastric carcinomas, activated PAR2 stimulates EGFR activity and thus cellular proliferation (Caruso et al, 2006); Darmoul et al., 2004). Indeed in ovarian cancer increase in PAR-2 was seen with progression of the cancer irrespective of the histopathological classification of the tumour type, and high cancer cell PAR-2 expression was associated with a significantly worse prognosis (Jahan et al., 2007). Similarly patients with lymph node metastases of uterine cancers with high levels of PAR-2 had significantly worse prognosis than those with lower levels (Jahan et al., 2008). PAR-2 has also been implicated in tumour angiogenesis in cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma (see Jahan et al, 2007).
Inflammation
PAR2 receptor activation has been shown to be important in inflammatory disorders. Based on in vivo studies in models of inflammatory disorders (Kelso et al, JPET, 2006, 316, 1017-1024, Sevigny, PNAS, 2011, 108, 20, 8491-8496 and Cenac et al, JDR, 2010, 89, 10, 1123-1128) it is expected that antagonism of the PAR2 receptor will be effective in the treatment of inflammatory disorders.
Pancreatitis
Pancreatitis is an inflammatory condition understood to be the result of undesirable trypsin activity within the pancreas. The biological effects of trypsin in the pancreas have been shown to act through PAR2, which is strongly expressed on the luminal surface of acinar and ductal cells (Ceppa et al., 2011). Antagonism of the effects of trypsin at PAR2, within the pancreas, can be expected to be an effective treatment for pancreatitis.'
For the above reasons, the PAR2 receptor is regarded as a target for intervention in the treatment of the conditions referred to above. There are few antagonists of PAR-2 available which are suitable for therapeutic treatment. Accordingly a small molecule antagonist is desirable for therapy.
Brief Description of the Invention
This invention makes available compounds which are antagonists of the PAR2 receptor, and their use in indications which respond to the antagonism of the PAR2 receptor such as those mentioned above.
Detailed Description of the Invention
According to the present invention there is provided a compound selected from:
N-[(4-Carbamimidoylphenyl)methyl]-3-phenylbenzamide hydrochloride,
N-[(4-Carbamimidoylphenyl)methyl]-3-[3-(acetamidomethyl)phenyl]benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -2 -phenylbenzamide,
N- [(4 -carbamimidoylphenyl)methyl] -3 - [5 -(acetamidomethyl)-2 -methylphenyl] -4 - methoxybenzamide, N-[(4-Carbamimidoylphenyl)methyl]-3-(pyridin-3-yl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -3 -( 1 H-pyrazol-5 -yl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -4 -phenylpyridine -2 -carboxamide ,
N-[(4-Carbamimidoylphenyl)methyl]-3-(pyridin-4-yl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -5 -phenylpyridine -3 -carboxamide ,
N- [(4 -Carbamimidoylphenyl)methyl] -3 -(2 -methylphenyl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -2 -hydroxy-5 -phenylbenzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-fluoro-5-phenylbenzamide,
2-(4-Bromophenyl)-N-[(4-carbamimidoylphenyl)methyl]benzamide,
N- [(4 -carbamimidoylphenyl)methyl] -2 -(pyridin-3 -yl)benzamide,
N- [(4 -carbamimidoylphenyl)methyl] -2 -(3 ,4 -dichlorophenyl)benzamide,
N- [(4 -carbamimidoylphenyl)methyl] -2 -(4 -chlorophenyl)benzamide,
N- [(4 -carbamimidoylphenyl)methyl] -2 -(4 -methoxyphenyl)benzamide,
N- [(4 -carbamimidoylphenyl)methyl] -4 -fluoro-2 -(4 -methoxyphenyl)benzamide , N- [(4 -carbamimidoylphenyl)methyl] -4 -fluoro-2 -(pyridin-3 -yl)benzamide,
N- [(4 -carbamimidoylphenyl)methyl] -2 -(3 ,4 -dichlorophenyl)-4 -fluorobenzamide ,
N- [(4 -carbamimidoylphenyl)methyl] -2 -(4 -chlorophenyl)-4 -fluorobenzamide,
1 -N-[(4-Carbamimidoylphenyl)methyl] -3 -N-(cyclopropylmethyl)-5 -phenylbenzene- 1,3- dicarboxamide,
N- [(4 -carbamimidoylphenyl)methyl] -2 - [4 -(trifluoromethyl)phenyl]benzamide, N- [(4 -Carbamimidoylphenyl)methyl] -2 -(4 -sulfamoylphenyl)benzamide,
2-amino-N-[(4-carbamimidoylphenyl)methyl]-5-phenylbenzamide,
N- [(4 -carbamimidoylphenyl)methyl] -2 -methyl-3 -phenylbenzamide,
N- [(4 -carbamimidoylphenyl)methyl] -4 -methyl-3 -phenylbenzamide,
N- [(4 -carbamimidoylphenyl)methyl] -4 -chloro-3 -phenylbenzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-chloro-3-phenylbenzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -4 -(4 -methoxyphenyl)pyridine-3 -carboxamide, N-[(4-carbamimidoylphenyl)methyl]-2-(3-methanesulfonylphenyl)benzamide, N- [(4 -Carbamimidoylphenyl)methyl] -4 -(4 -sulfamoylphenyl)pyridine-3 -carboxamide, N- [(4 -Carbamimidoylphenyl)methyl] -3 -(4 -sulfamoylphenyl)pyridine-4 -carboxamide, N- [(4 -Carbamimidoylphenyl)methyl] -3 -(4 -sulfamoylphenyl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -3 -(3 -sulfamoylphenyl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -3 - [2 -(dimethylsulfamoyl)phenyl]benzamide, N- [(4 -Carbamimidoylphenyl)methyl] -2 - [4 -(sulfamoylamino)phenyl]benzamide, N- [(4 -Carbamimidoylphenyl)methyl] -4 -fluoro-2 -(4 -sulfamoylphenyl)benzamide, 4-[(3 -Phenylbenzene)sulfonamidomethyl] benzene- 1 -carboximidamide,
N- [(4 -Carbamimidoylphenyl)methyl] -3 -( 1 -methyl- 1 H-imidazol-2 -yl)benzamide, N- [(4 -Carbamimidoylphenyl)methyl] -2 - [4 -(methylsulfamoyl)phenyl]benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -2 - { 4 - [(propan-2 -yl)sulfamoyl]phenyl } benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -2 - [4 -(dimethylsulfamoyl)phenyl]benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -2 -(3 -methyl -4 -sulfamoylphenyl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -2 -(3 -fluoro-4 -sulfamoylphenyl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -3 -(2 -methyl -4 -sulfamoylphenyl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -2 -(4 -carbamoylphenyl)benzamide,
N- [(4 -carbamimidoylphenyl)methyl] -2 -(2 -methyl-4 -sulfamoylphenyl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -2 - [4 -(moφholine -4 -sulfonyl)phenyl]benzamide,
N- [(4 -Carbamimidoyl-2 -chlorophenyl)methyl] -3 -phenylbenzamide,
N- [(4 -Carbamimidoyl-2 -methylphenyl)methyl] -3 -phenylbenzamide ,
N- [(4 -carbamimidoylphenyl)methyl] -2 -(4 -methanesulfonamido phenyl)benzamide,
N- [(4 -Carbamimidoylphenyl)methyl] -3 -(3 -cyanophenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-3 -phenyl- 1 ,2-thiazole-5 -carboxamide,
N-[(4-Carbamimidoylphenyl)methyl]-5-phenyl-lH-pyrazole-3-carboxamide
N-[(4-Carbamimidoylphenyl)methyl]-3 -phenyl- 1 ,2-thiazole-4-carboxamide,
or a pharmaceutically acceptable salt, solvate or hydrate thereof.
Compounds of formula (I) above may be prepared in the form of salts, especially pharmaceutically acceptable salts, N-oxides, hydrates, solvates and polymorphic forms thereof. Any claim to a compound herein, or reference herein to "compounds of the invention", "compounds with which the invention is concerned", "compounds of formula (I)" and the like, includes salts, N-oxides, hydrates, solvates and polymorphs of such compounds;
Although the above definition potentially includes molecules of high molecular weight, it is preferable, in line with general principles of medicinal chemistry practice, that the compounds with which this invention is concerned should have molecular weights of no more than 600.
The compounds of the invention are antagonists of the PAR2 receptor. Therefore, in another broad aspect the invention provides the use of a compound of the invention in the treatment of, or in the preparation of a composition for treatment of, diseases or conditions responsive to the reduction of PAR2 mediated activity. Examples of diseases or conditions which are responsive to the reduction of PAR2 mediated activity include inflammation including intestinal inflammation (such as ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome), fibrosis, arthritis and inflammatory skin diseases (such as psoriasis, atopic dermatitis and itch), pain and cancers including cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma.
The compounds with which the invention is concerned may be used for the reduction of PAR2 mediated activity, ex vivo or in vivo.
In one aspect of the invention, the compounds of the invention may be used in the preparation of a composition for the treatment of diseases or conditions selected from inflammation including intestinal inflammation (such as ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome), fibrosis, arthritis and inflammatory skin diseases (such as psoriasis, atopic dermatitis and itch), pain and cancers including cancers of the breast, colon, gastrium, pancreas, lungs, prostate, melanoma and glioblastoma.
In another aspect, the invention provides a method for the treatment of the foregoing disease types, which comprises administering to a subject suffering such disease an effective amount of a compound of the invention.
In another aspect of the invention there is provided a pharmaceutical composition comprising a compound of the invention together with one or more pharmaceutically acceptable carriers and/or excipients.
The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds can be administered in a sublingual formulation, for example a buccal formulation. The compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally, by inhalation, intranasally, or by infusion techniques. The compounds may also be administered as suppositories. The compounds may also be administered topically. Thus, the compounds of the invention are administered orally, or by inhalation, topically, or intranasally. In a preferred embodiment, the compounds of the invention are administered orally and more preferably, the compounds of the invention are administered as a tablet or capsule. In the latter connection, administration of the compounds in a hard gelatine capsule form, or in one of the many sustained release formulations known in the art will often be preferred. In an alternative preferred embodiment the compounds of the invention are administered as a topical treatment.
The present invention further provides a pharmaceutical composition containing a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above, and a pharmaceutically acceptable carrier.
The compounds of the invention are typically formulated for administration with a pharmaceutically acceptable carrier or diluent. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar coating, or film coating processes. Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol. Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
Since the compounds of the invention are preferably administered orally, the present invention further provides a pharmaceutical composition containing a compound of the invention or a pharmaceutically acceptable salt thereof, as defined above, and a pharmaceutically acceptable carrier in the form of a capsule or tablet.
Alternatively, the compounds of the invention are preferable administered topically. The compounds may be formulated in any form suitable for topical administration including semi-solid, spray, medicated powders, solution, and medicated adhesive systems. Once formulated, the compounds of the invention may be administered as external topicals that are spread, sprayed, or otherwise dispersed on to cutaneous tissues to cover the affected area. Topical drug delivery is especially effective in the fields of psoriasis, itch, and pain management. Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the art. However, it is expected that a typical dose will be in the range from about 0.001 to 50 mg per kg of body weight.
Terminology
The following definitions shall apply throughout the specification and the appended claims, unless otherwise stated or indicated. Compounds of the invention may exist in one or more geometrical, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and ^raws-forms, E- and Z-forms, R-, S- and meso-iorms, keto-, and enol-forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers may be prepared by the application of adaptation of known methods (e.g. asymmetric synthesis). As used herein the term "salt" includes base addition, acid addition and ammonium salts. As briefly mentioned above compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like. Those compounds of the invention which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, trifluoroacetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p- toluenesulphonic, benzoic, benzenesulfonic, glutamic, lactic, and mandelic acids and the like. Those compounds (I) which have a basic nitrogen can also form quaternary ammonium salts with a pharmaceutically acceptable counter-ion such as chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene- bis sulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like. For a review on salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley- VCH, Weinheim, Germany, 2002). It is expected that compounds of the invention may be prepared in the form of hydrates, and solvates. Any reference herein, including the claims herein, to "compounds with which the invention is concerned" or "compounds of the invention" or "the present compounds", and the like, includes reference to salts, hydrates, and solvates of such compounds. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.
Individual compounds of the invention may exist in an amorphous form and /or several polymorphic forms and may be obtained in different crystal habits. Any reference herein, including the claims herein, to "compounds with which the invention is concerned" or "compounds of the invention" or "the present compounds", and the like, includes reference to the compounds irrespective of amorphous or polymorphic form. Some compounds of the invention, having a nitrogen atom in an aromatic ring, may form N-oxides, and the invention includes compounds of the invention in their N-oxide form.
It is contemplated that the intermediates described herein can also be used as therapeutic agents to treat or more of the diseases or conditions described throughout.
Synthesis
The compounds of the invention may be prepared by, or in analogy with, conventional methods. The preparation of intermediates and compounds according to the Examples of the present invention are illustrated as follows.
The following abbreviations have been used:
Ac20 Acetic anhydride
AcOH Acetic acid
aq aqueous
Boc tert-Butyloxycarbonyl
BSA Bovine serum albumin
Calcd Calculated
DCM Dichloromethane
DIPEA N,N-Diisopropylethylamine
DMF N,N-Dimethylformamide
DMSO Dimethyl sulfoxide
EDC 1 -Ethyl-3 -(3 -dimethylaminopropyl)carbodiimide
EDTA Ethylenediaminetetraacetic acid
ES+ Electrospray (positive ion mode)
ES- Electrospray (negative ion mode)
Et20 Diethyl ether
EtOAc Ethyl acetate
EtOH Ethanol
Ex Example
HBSS Hank's Buffered Salt Solution
HEPES 4-(2 -Hydroxy ethyl)- 1 -piperazineethanesulfonic acid
HOBt Hydroxybenzotriazole
HONB N-Hydroxy-5-norbornene-2,3-dicarboximide
HPLC High Performance Liquid Chromatography HRMS High Resolution Mass Spectrometry
Int Intermediate
LCMS Liquid Chromatography Mass Spectrometry
M Molar
MeCN Acetonitrile
MeOH Methanol
[MH]+ Protonated molecular ion
MSD-TOF Mass Selective Detector-Time of Flight
PAR Protease activated receptor
PBS Phosphate buffered saline
PyBop Benzotria )3-l-yl-oxytripyrrolidinophosphoniuni hexafluorophosphate
Rt Retention time
sat saturated
TFA Trifluoroacetic acid
THF Tetrahydrofuran
TLC Thin Layer Chromatography
EXAMPLES AND INTERMEDIATE COMPOUNDS
Experimental Methods
All reagents were commercial grade and were used as received without further purification, unless otherwise specified. Reagent grade solvents were used in all cases. Analytical LCMS was performed on either an Agilent 1100 system equipped with a Phenomenex Synergi, RP-Hydro, 150 x 4.6mm, 4um column (MeCN in water (+0.085% TFA), 200-3 OOnm, 30°C) or Agilent 1100 system equipped with a Phenomenex Gemini, C18, 100 x 4.6mm, 4um column (MeCN in water (lOmM ammonium bicarbonate), 200- 3 OOnm, 40°C). Accurate masses, where present, were measured using a Waters QTOF electrospray ion source and corrected using Leucine Enkephalin lockmass. Spectra were acquired in positive electrospray mode. The acquired mass range was m/z 100-1000. Samples were dissolved in DMSO to give Img/mL solutions which were then further diluted with Acetonitrile (50%) / Water (50%) to ^g/mL solutions prior to analysis. The values reported correspond to the protonated molecular ions [MH]+. Analytical HPLC was performed on an Agilent 1100 system using a Phenomenex Synergi, RP-Hydro, 150 x 4.6mm, 4um column with a flow rate of 1.5mL per min at 30°C (200-3 OOnm) and a gradient of 5-100% MeCN (+0.085% TFA) in water (+0.1% TFA) over 7min. Mass directed HPLC was performed on a Waters system using a Phenomenex Gemini, CI 8, 100 x 21mm, 5um column with a flow rate of 20mL per min over 14.5min. Flash chromatography was performed on either a CombiFlash Companion system equipped with RediSep silica columns or a Flash Master Personal system equipped with Strata SI- 1 silica gigatubes or in a glass column under gravity. Reverse Phase HPLC was performed on a Gilson system (Gilson 322 pump with Gilson 321 equilibration pump and Gilson 215 autosampler) equipped with Phenomenex Synergi Hydro RP 150 x 10mm, or YMC ODS-A 100/150 x 20mm columns. Microwave irradiations were carried out using a Biotage microwave. Hydrogenations were performed using a Thales H-cube Nano. Reactions were performed at room temperature unless otherwise stated. The compounds were automatically named using ACD 6.0. All compounds were dried in a vacuum oven overnight. Where yields are not included, the intermediates were used crude. Reactions were monitored by TLC, LCMS or HPLC.
INTERMEDIATE 1
-Dimethyl 5-bromobenzene-l,3-dicarboxylate
Figure imgf000015_0001
5-Bromobenzene-l,3-dicarboxylic acid (l.OOg, 4.08mmol) was dissolved in DCM (20mL) and oxalyl chloride (876uL, 10.2mmol) and DMF (200uL) were added. The reaction mixture was stirred for 2h and concentrated in vacuo. The residue was dissolved in MeOH (20mL), stirred for 18h and partitioned between DCM (lOOmL) and sat aq Na2CC>3 (50mL). The aqueous fraction was extracted with DCM (50mL) and the combined organic fractions were dried (MgSC^) and concentrated in vacuo. The residue was purified by column chromatography to give the title compound (1.04g, 93%) as a white solid. LCMS: ES+ 272.9, 274.9 [MH]+.
INTERMEDIATE 2
1,3-Dimethyl 5-phenylbenzene-l,3-dicarboxylate
Figure imgf000015_0002
Intermediate 1 (1.04g, 3.81mmol), phenylboronic acid (510mg, 4.19mmol), Pd(PPli3)4 (220mg, 0.19mmol) and CS2CO3 (1.36g, 4.19mmol) were dissolved in water (2mL),
PhMe (21mL) and EtOH (4mL). The reaction mixture was heated under reflux at 100°C for 6h, filtered through celite and concentrated in vacuo. The residue was purified by column chromatography to give the title compound (843 mg, 82%) as a white solid. LCMS: ES+ 271.2 [MH]+.
INTERMEDIATE 3
-(Ethoxycarbonyl)-5-phenylbenzoic acid
Figure imgf000016_0001
Intermediate 2 (843mg, 3.12mmol) was dissolved in dioxane (lOmL) and EtOH (30mL), Lithium hydroxide monohydrate (260mg, 6.21mmol) was added and the reaction mixture was stirred 3d. The reaction mixture was acidified to pH 2 with 1M aq HC1, diluted with water (lOmL) and extracted with EtOAc (3x20mL). The combined organic fractions were washed with brine (lOmL), dried (MgSO^ and concentrated in vacuo to give the title compound (843mg, 100%) as a white solid. LCMS: ES+ 271.3 [MH]+.
INTERMEDIATE 4
4'-Meth lsulfamoyl-biphenyl-2-carboxylic acid
Figure imgf000016_0002
2-Carboxybenzeneboronic acid (0.20g, 1.21mmol), 4-bromo-N- methylbenzenesulphonamide (0.36g, 1.45mmol), Na2C03 (0.26g, 2.42mmol) and Pd(PPh3)4 (140mg, 0.12mmol) were suspended in dioxane/water (4mL, 1 : 1) and heated using a microwave reactor at 150°C for 20min. The reaction mixture was concentrated in vacuo, dissolved in EtOAc (30mL) and washed with water (2x3 OmL). The combined aqueous fractions were acidified to pH 1 with 1M aq HC1 and extracted with EtOAc (2x3 OmL). The combined organic fractions were washed with brine (3 OmL), dried (MgSO^ and concentrated in vacuo to give the title compound (259mg, 74%) as a white solid. LCMS: ES+ 292.0 [MH] . INTERMEDIATE 5
2- 4- [(Propan-2-yl)sulfamoyl] phenyl} benzoic
Figure imgf000017_0001
4-Chlorobenzenesulfonyl chloride (150mg, 0.71mmol), isopropylamine (0.18mL, 2.13mmol) and DIPEA (0.13mL, 0.78mmol) were dissolved in THF and stirred for lh. The reaction mixture was concentrated in vacuo and purified by column chromatography. The residue, 2-carboxybenzeneboronic acid (210mg, 1.42mmol), Pd(PPh3)4 (70.0mg, 0.06mmol) and Na2C03 (130mg, 1.24mmol) were suspended in dioxane / water (4mL, 1 :1) and heated using a microwave reactor at 150°C for 20min. The reaction mixture was concentrated in vacuo and purified by column chromatography. The residue was suspended in Et^O, sonicated, filtered and concentrated in vacuo to give the title compound (91.0mg, 40%) as a pale yellow solid. LCMS: ES+ 320.0 [MH]+.
INTERMEDIATE 6
4'-Dimeth lsulfamoyl-biphenyl-2-carboxylic acid
Figure imgf000017_0002
Intermediate 6 was prepared similarly to Intermediate 5, using dimethylamine instead of isopropylamine, to give the title compound (238mg, 82%) as a white solid. LCMS: ES+ 306.0 [MH]+.
INTERMEDIATE 7
2- [4-(Morpholine-4-sulfonyl)phenyl] benzoic OH
0=S = 0
In όtermediate 7 was prepared similarly to Intermediate 5, using morpholine instead of isopropylamine, to give the crude title compound (432mg) as a white solid. LCMS: ES+ 348.0 [MH]+.
INTERMEDIATE 8
3'-Meth l-4'-sulfamoyl-biphenyl-2-carboxylic acid
Figure imgf000018_0001
2-Carboxybenzeneboronic acid (200mg, 1.21mmol), 4-bromo-2- methylbenzenesulphonamide (360mg, 1.45mmol), Na2C03 (0.26g, 2.42mmol) and Pd(PPh3)4 (140mg, 0.12mmol) were suspended in dioxane / water (4mL, 1 : 1) and heated using a microwave reactor at 150°C for 20min. The reaction mixture was concentrated in vacuo, dissolved in EtOAc (30mL) and washed with 1M aq Na2CC>3 (2x30mL). The combined aqueous fractions were acidified to pH 1 with 1M aq HC1 and extracted with EtOAc (2x40mL). The combined organic fractions were washed with brine (50mL), dried (MgSC^) and concentrated in vacuo to give the title compound (273 mg, 78%) as a yellow solid. LCMS: ES+ 292.0 [MH]+.
INTERMEDIATE 9
3'-Fluoro-4'-sulfamoyl-biphenyl-2-carboxylic acid
Figure imgf000018_0002
Intermediate 9 was prepared similarly to Intermediate 8, using 4-bromo-2- fluorobenzenesulphonamide instead of 4-bromo-2-methylbenzenesulphonamide, to give the crude title compound (360mg) as a white solid. LCMS: ES+ 296.0 [MH]+.
INTERMEDIATE 10
2- 3-(4-sulfamoylphenyl)phenyl] acetic acid
Figure imgf000019_0001
Intermediate 10 was prepared similarly to Intermediate 8 using 2-(3-bromophenyl)acetic acid instead of 4-bromo-2-methylbenzenesulphonamide and (4- sulfamoylphenyl)boronic acid instead of 2-carboxybenzeneboronic acid, to give the crude title compound (1.09g) as a black solid. LCMS: ES+ 291.9 [MH]+.
INTERMEDIATE 11
3- 2-Methyl-4-sulfamoylphenyl)benzoic
Figure imgf000019_0002
Intermediate 11 was prepared similarly to Intermediate 8, using 4-bromo-3- methylbenzenesulphonamide instead of 4-bromo-2-methylbenzenesulphonamide and 3- methoxycarbonylphenylboronic acid instead of 2-carboxybenzeneboronic acid, to give the title compound (218mg, 27%) as a white solid. LCMS: ES+ 292.0 [MH]+.
INTERMEDIATE 12
2- 4-Carbamoylphenyl)benzoic
Figure imgf000019_0003
Intermediate 12 was prepared similarly to Intermediate 8, using 4-bromobenzamide instead of 4-bromo-2-methylbenzenesulphonamide and 2- methoxycarbonylphenylboronic acid instead of 2-carboxybenzeneboronic acid, to give the title compound (216mg, 54%) as a grey solid. LCMS: ES+ 242.0 [MH] .
INTERMEDIATE 13
2'-Meth l-4'-sulfamoyl-biphenyl-2-carboxylic acid
Figure imgf000020_0001
Intermediate 13 was prepared similarly to Intermediate 8, using 4-bromo-3- methylbenzenesulphonamide instead of 4-bromo-2-methylbenzenesulphonamide, to give the crude title compound (161mg) as a white solid. LCMS: ES+ 292.0 [MH]+.
INTERMEDIATE 14
-Bromo-2-chlorophenyl)methanol
Figure imgf000020_0002
4-Bromo-2-chlorobenzoic acid (4.70g, 20.0mmol) was dissolved in THF (50mL), cooled and 1M BH3 in THF (22mL, 22.0mmol) was added drop-wise. The reaction mixture was stirred at room temperature overnight, cooled to -10°C, quenched with water (15mL), poured onto sat aq NaHC03 (lOOmL) and extracted with EtOAc. The combined organic fractions were washed with water, brine, dried (MgSC^) and concentrated in vacuo to give the crude title compound (4.45g) as a white solid. LCMS: ES+ 220 [MH]+.
INTERMEDIATE 15
-Bromo-2-methylphenyl)methanol
Figure imgf000020_0003
Intermediate 15 was prepared similarly to Intermediate 14, using 4-bromo-2- methylbenzoic acid instead of 4-bromo-2-chlorobenzoic acid, to give the title compound (8.80g, 88%) as a white solid. LCMS: ES" 199 [M-H]".
INTERMEDIATE 16
3-Chloro-4-(hydroxymethyl)benzonitrile
Figure imgf000021_0001
Intermediate 14 (1.77g, 8.00mmol), ZnCN2 (564mg, 4.80mmol) and Pd(PPh3)4 (370mg, 0.32mmol) were dissolved in DMF (20mL) and the reaction mixture was heated at 100°C overnight. The reaction mixture was cooled to room temperature, diluted with water, brine and EtOAc and filtered through celite. The aqueous fraction was extracted with EtOAc and the combined organic fractions were washed with 2M aq NH4OH, brine, dried (MgSC^) and concentrated in vacuo. The residue was triturated from hexanes to give the crude title compound (1.15g) as a pink solid. LCMS: ES+ 167.2 [MH]+.
INTERMEDIATE 17
-(Hydroxymethyl)-3-methylbenzonitrile
Figure imgf000021_0002
Intermediate 17 was prepared similarly to Intermediate 16, using Intermediate 15 instead Intermediate 14, to give the title compound (4.70g, 41%) as a white solid. LCMS: ES" 146 [M-H]".
INTERMEDIATE 18
-(Bromomethyl)-3-chlorobenzonitrile
Figure imgf000021_0003
Intermediate 16 (5.03g, 30.0mmol) and CBr4 (10.9g, 33.0mmol) were suspended in DCM (90mL), cooled to 5°C and PPh3 (8.66g, 33.0mmol) was added. The reaction mixture was stirred at room temperature for 2.5h. Hexane / EtOAc (200mL, 9:1) was added and the reaction mixture was filtered. The filtrate was concentrated in vacuo and purified by normal phase chromatography to give the title compound (6.20g, 90%) as a white solid. HPLC: 98% purity.
INTERMEDIATE 19
4-(Bromomethyl)-3-methylbenzonitrile
Figure imgf000022_0001
Intermediate 19 was prepared similarly to Intermediate 18, using Intermediate 17 instead Intermediate 16, to give the title compound (5.50g, 90%) as a white solid. INTERMEDIATE 20
-(Aminomethyl)-3-chlorobenzonitrile hydrochloride
Figure imgf000022_0002
Intermediate 18 (4.61g, 20.0mmol) was dissolved in THF (20mL) and added drop-wise to a suspension of NaH (960mg, 60% suspension in mineral oil, 24.0mmol) in THF (20mL) at 5°C. A solution of (Boc)2NH (4.80g, 22.0mmol) in THF (20mL) was added drop-wise over lOmin and the reaction mixture was stirred at 5°C for 15min and warmed to room temperature overnight. The reaction mixture was quenched with 15% aq NH4C1 (50mL) and the THF was removed in vacuo. The aqueous solution was diluted with brine and extracted with DCM (1L). The organic fraction was washed with brine, dried (MgSCu) and concentrated in vacuo. The residue was dissolved in EtOAc (150mL), cooled and HC1 (g) was bubbled through the solution for 15min. The reaction mixture was stirred at room temperature for 6h and allowed to stand at 5°C overnight. The resulting precipitate was collected by filtration and washed with hexanes to give the crude title compound (3.47g, 85%) as a white solid.
INTERMEDIATE 21
-(Aminomethyl)-3-methylbenzonitrile hydrochloride
Figure imgf000022_0003
Intermediate 21 was prepared similarly to Intermediate 20, using Intermediate 19 instead Intermediate 18, to give the title compound (3.25g, 89%) as a white solid.
INTERMEDIATE 22
N- [(4-Cyanophenyl)methyl] -3-phenylbenzamide
Figure imgf000023_0001
Biphenyl-3-carboxylic acid (500mg, 2.52mmol) and 4-aminomethyl-benzonitrile (425mg, 2.52mmol) were suspended in DCM (25mL) and DIPEA (873uL, 5.04mmol), EDC (484mg, 2.52mmol) and HOBt (386mg, 2.52mmol) were added. The reaction mixture was stirred overnight, concentrated in vacuo and partitioned between EtOAc (lOOmL) and water (lOOmL). The organic fraction was washed with water (lOOmL), sat aq NaHC03 (50mL), brine (50mL), dried (MgSC^) and concentrated in vacuo to give the title compound (738mg, 94%) as a brown solid. LCMS: ES+ 313.0 [MH]+.
INTERMEDIATE 23
- [(2-Chloro-4-cyanophenyl)methyl] -3-phenylbenzamide
Figure imgf000023_0002
Intermediate 23 was prepared similarly to Intermediate 22, using Intermediate 20 instead of 4-aminomethyl-benzonitrile, to give the title compound (1.44g, 69%) as a white solid. LCMS: ES+ 347.1 [MH]+.
INTERMEDIATE 24
- [(4-Cyano-2-methylphenyl)methyl] -3-phenylbenzamide
Figure imgf000023_0003
Intermediate 24 was prepared similarly to Intermediate 22, using Intermediate 21 instead of 4-aminomethyl-benzonitrile, to give the title compound (1.20g, 61%) as a white solid. LCMS: ES+ 327 [MH]+.
INTERMEDIATES 25-39
Intermediates 25-39 were prepared similarly to Intermediate 22 using 4-aminomethyl- benzonitrile and the appropriate carboxylic acid; see Table 1 below.
Table 1: Amide couplings. Int Structure Name Yield LCMS
N-[(4-Cyanophenyl)methyl]-2- ES+ 313.1
25 81%
phenylbenzamide [MH]+
2-(4-Bromophenyl)-N-[(4- Used ES+ 391.1
26
cyanophenyl)methyl]benzamide crude [MH]+
Br
4'-Amino-biphenyl-2-carboxylic Used ES+ 328.0
27
acid 4-cyano-benzylamide crude [MH]+
NH2
N-[(4-Cyanophenyl)methyl]-2- Used ES+ 314.3
28
(pyridin-3 -yl)benzamide crude [MH]+
Used
N-[(4-Cyanophenyl)methyl]-2-[4- crude ES+ 405.9
29 (methylsulfamoyl)phenyl]
from [MH]+ benzamide
o=s=o Int 4
^NH
Used
N-[(4-Cyanophenyl)methyl]-2-{4- crude ES+ 434.0
30 [(propan-2-yl)sulfamoyl]phenyl}
from [MH]+ o=s=o benzamide
Int 5
Figure imgf000025_0001
Figure imgf000026_0001
INTERMEDIATE 40
-{[(4-Cyanophenyl)methyl]carbamoyl}-5-phenylbenzoic acid
Figure imgf000026_0002
Intermediate 38 (711mg, 1.85mmol) was dissolved in THF/water (40mL, 1 :1), lithium hydroxide monohydrate (171mg, 4.07mmol) was added and the reaction mixture was stirred for 18h. The THF was removed in vacuo and the aqueous solution was acidified to pH 1 with 1M aq HCl and extracted with EtOAc (3x50mL). The combined organic fractions were dried (MgSC^) and concentrated in vacuo to give the title compound (415mg, 63%) as a white solid. LCMS: ES+ 357.2 [MH]+.
INTERMEDIATE 41
l-N-[(4-Cyanophenyl)methyl]-3-N-(cyclopropylmethyl)-5-phenylbenzene-l,3- dicarboxamide
Figure imgf000027_0001
Intermediate 40 (200mg, 0.56mmol) was dissolved in DCM (5mL), EDC.HC1 (131mg, 0.84mmol), HONB (151mg, 0.84mmol), cyclopropanemethylamine (49uL, 0.56mmol) and DIPEA (440uL, 2.53mmol) were added and the reaction mixture was stirred for 18h. The reaction mixture was concentrated in vacuo and partitioned between DCM (lOOmL) and sat aq Na2CC>3 solution (50mL). The aqueous fraction was extracted with DCM
(50mL) and the combined organic fractions were dried (MgSC^) concentrated in vacuo.
The residue was purified by column chromatography to give the title compound (121mg, 53%) as a white solid. LCMS: ES+ 410.2 [MH]+.
INTERMEDIATE 42
-Bromo-N- [(4-cyanophenyl)methyl] benzamide
Figure imgf000027_0002
3-Bromobenzoic acid (2.51g, 12.5mmol) was dissolved in DCM (40mL), oxalyl chloride (1.95mL, 22.7mmol) and DMF (lOOuL) were added and the reaction mixture was stirred for 2h. The reaction mixture was concentrated in vacuo and the residue was dissolved in DCM (40mL) and DIPEA (9.88mL, 56.8mmol), and 4-(aminomethyl)benzonitrile (1.50g, 11.4mmol) was added. The reaction mixture was stirred for 3d and partitioned between DCM (200mL) and sat aq Na2CC>3 (lOOmL). The aqueous fraction was extracted with DCM (lOOmL) and the combined organic fractions were dried (MgSC^) and concentrated in vacuo to give the crude title compound (3.58g) as a brown gum. LCMS: ES+ 314.9, 316.8 [MH]+.
INTERMEDIATES 43-51
Intermediates 43-51 were prepared similarly to Intermediate 42, using 4- (aminomethyl)benzonitrile and the appropriate carboxylic acid; see Table 2 below.
Table 2: Amide couplings. Int Structure Name Yield LCMS
2- Amino-5 -bromo-N- [(4- LCMS: ES+ 330.9,
43 20%
cyanophenyl)methyl]benzamide 331.9 [MH]+ o
3-Bromo-4-chloro-N-[(4- LCMS: ES+ 348.8,
44 78%
cyanophenyl)methyl]benzamide 350.9 [MH]+ o
3-Bromo-2-chloro-N-[(4- LCMS: ES+ 348.8,
45 58%
cyanophenyl)methyl]benzamide 350.9 [MH]+
CI o
4-Chloro-N-[(4-
LCMS: ES+ 271.9
47 cyanophenyl)methyl]pyridine-3 - 69%
[MH]+
CI o carboxamide
2-Chloro-N-[(4- LCMS: ES+ 271.2
48 54%
cyanophenyl)methyl]benzamide [MH]+
CI o
3 -Bromo-N- [(4-
LCMS: ES+ 315.9,
49 cyanophenyl)methyl]pyridine-4- 72%
317.9 [MH]+
Br O carboxamide
2-Chloro-N-[(4-
LCMS: ES+ 289.1
50 cyanophenyl)methyl] -4- 57%
[MH]+
CI o fluorobenzamide
3 -(3 -Bromophenyl)-N- [(4-
LCMS: ES+ 342.9,
51 cyanophenyl)methyl] 75%
344.8 [MH]+
O propanamide
INTERMEDIATE 52
N- [(4-Cyanophenyl)methyl] -3- [3-(acetamidomethyl)phenyl] benzamide
Figure imgf000028_0001
Intermediate 42 (575mg, 1.82mmol), N-{[3-
(dihydroxyboranyl)phenyl]methyl}acetamide (352mg, 1.82mmol), Pd(PPh3)4 (169mg, 0.146mmol) and Na2CC>3 (483mg, 4.56mmol) were dissolved in water (2mL) and dioxane (2mL) and heated using a microwave reactor at 150°C for 20min. The reaction 5 mixture was concentrated in vacuo and the residue was partitioned between DCM (50mL) and water (30mL). The aqueous fraction was extracted with DCM (30mL) and the combined organic fractions were dried (MgSC^) and concentrated in vacuo. The residue was purified by column chromatography to give the title compound (401mg, 57%) as a yellow solid. LCMS: ES+ 384.0 [MH]+.
10
INTERMEDIATES 53-84
Intermediates 53-84 were prepared similarly to Intermediate 52 using Intermediate 42 (unless otherwise stated) and the appropriate boronic acid / ester; see Table 3 below.
15 Table 3: Suzuki couplings.
Figure imgf000029_0001
N-[(4-Cyanophenyl)methyl]-3-(2- ES+ 327.2
42%
methylphenyl)benzamide [MH]+ o
N-[(4-Cyanophenyl)methyl]-2- ES+ 329.3
9%
hydroxy-5-phenylbenzamide [MH]+ o
N-[(4-Cyanophenyl)methyl]-2- ES+ 331.2
30%
fluoro-5-phenylbenzamide [MH]+ o
N-[(4-Cyanophenyl)methyl]-2- Used ES+ 381.1 (3 ,4-dichlorophenyl)benzamide crude [MH]+
2-(4-Chlorophenyl)-N-[(4- Used ES+ 347.2 cyanophenyl)methyl]benzamide crude [MH]+
N-[(4-Cyanophenyl)methyl]-2-(4- Used ES+ 343.2 methoxyphenyl)benzamide crude [MH]+
N-[(4-Cyanophenyl)methyl]-4-
Used ES+ 361.2 fluoro-2-(4- crude [MH]+ methoxyphenyl)benzamide
N-[(4-Cyanophenyl)methyl]-4- Used ES+ 332.3 fluoro-2-(pyridin-2-yl)benzamide crude [MH]+
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
INTERMEDIATE 85
tert-Butyl N-{[4-(2-{[(4- cyanophenyl)methyl] carbamoyl} phenyl)phenyl] sulfamoyl} carbamate
Figure imgf000033_0002
Chlorosulfonyl isocyanate (27.0uL, 0.31mmol) was dissolved in DCM (lmL), cooled to 0°C and i-butanol (29.0uL, 0.31mmol) was added. The reaction mixture was stirred for 90min and added drop-wise with EtsN (0.14mL, l.Olmmol) to a solution of Intermediate 27 (lOOmg, 0.31mmol) and Et3N (0.08mL, 0.58mmol) in DCM at 0°C. The reaction
10 mixture was warmed to room temperature, stirred for 3h, diluted with DCM (20mL) and washed with sat aq NH4C1 (20mL), brine (20mL), dried (MgSC^) and concentrated in vacuo. The residue was dissolved in EtOAc (5mL), filtered and purified by column chromatography to give the title compound (120mg, 82%) as a yellow oil.
15 INTERMEDIATE 86 - [(4-Cyanophenyl)methyl] -3-phenylbenzene- 1-sulfonamide
Figure imgf000034_0001
3- Phenylbenzene-l-sulfonyl chloride (250mg, 0.99mmol), EtsN (412uL, 2.97mmol) and
4- (aminomethyl)benzonitrile (261mg, 1.98mmol) were dissolved in DCM (lOmL) and stirred for 3h. The reaction mixture was quenched with water and diluted with DCM
(50mL). The organic fraction was washed with brine (30mL), dried (MgSC^) and concentrated in vacuo to give the crude title compound (345mg) as a yellow liquid. LCMS: ES+ 349.0 [MH]+. INTERMEDIATE 87
Eth l 3-(3-cyanophenyl)benzoate
Figure imgf000034_0002
Ethyl 3-iodobenzoate (939mg, 3.40mmol) was dissolved in DMF (2mL) and a solution of 3-cyanophenylboronic acid (500mg, 3.40mmol) in DMF (5mL) was added. A solution of Pd(OAc)2 (15mg, 0.068mmol) and Na2C03 (858mg, 10.2mmol) in water (2mL) was added and the reaction mixture was heated at 110°C for 2d. The reaction mixture was concentrated in vacuo and partitioned between DCM (150mL) and water (50mL). The aqueous fraction was extracted with DCM (50mL) and the combined organic fractions were dried (MgS04) and concentrated in vacuo. The residue was purified by column chromatography to give the title compound (767mg, 90%) as a pale yellow liquid. LCMS: ES+ 252.1 [MH]+.
INTERMEDIATE 88
3- 3-Cyanophenyl)benzoic
Figure imgf000034_0003
Intermediate 87 (767mg, 3.05mmol) was dissolved in THF/water (20mL, 1 :1), Lithium hydroxide monohydrate (282mg, 6.72mmol) was added and the reaction mixture was stirred for 18h. The THF was removed in vacuo and the aqueous fraction was acidified to pH 1 with 1M aq HC1 and extracted with EtOAc (3x3 OmL). The combined organic fractions were dried (MgSC^) and concentrated in vacuo to give the title compound (600mg, 88%) as a white solid. LCMS: ES+ 224.0 [MH]+.
INTERMEDIATE 89
Eth l 3-(l-methyl-lH-imidazol-2-yl)benzoate
Figure imgf000035_0001
1-Methyl-lH-imidazole (446mg, 5.43mmol) was dissolved in THF (40mL) and the reaction mixture was cooled to -78°C. n-Butyllithium (3.5mL, 1.6M in hexanes, 5.61mmol) was added drop-wise over 30min and the reaction mixture was stirred at - 78°C for 30min. The reaction mixture was warmed to 0°C and a solution of zinc (II) chloride (2.22g, 16.3mmol) in ether (16.3mL) was added drop-wise over lOmin. The reaction mixture was stirred at 0°C for lh and at room temperature for 30min. Ethyl 3- iodobenzoate (l.OOg, 3.62mmol) and Pd(PPh3)4 (210mg, 0.18mmol) were added and the reaction mixture was heated under reflux at 65°C for lh, cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography to give the title compound (145mg, 17%) as a yellow gum. LCMS: ES+ 231.2 [MH]+.
INTERMEDIATE 90
3- l-Methyl-lH-imidazol-2-yl)benzoic acid
Figure imgf000035_0002
Intermediate 89 (145mg, 0.63mmol) was dissolved in THF/water (lOmL, 1 :1), lithium hydroxide monohydrate (58.0mg, 1.39mmol) was added and the reaction mixture was stirred for 18h. The THF was removed in vacuo and the aqueous solution was acidified to pH 1 with 1M aq HC1 and concentrated in vacuo to give the crude title compound (127mg) as a brown gum. LCMS: ES+ 203.2 [MH]+.
INTERMEDIATE 91
N-[(4-Cyanophenyl)methyl]-3-(l-methyl-lH-imidazol-2-yl)benzamide
Figure imgf000035_0003
Intermediate 90 (127mg, 0.63mmol) and 4-(aminomethyl)benzonitrile.HCl (106mg, 0.63mmol) were dissolved in DCM (5mL) and DIPEA (493uL, 2.83mmol). EDC (147mg, 0.94mmol) and HONB (169mg, 0.94mmol) were added. The reaction mixture was stirred for 18h and partitioned between DCM (20mL) and sat aq Na2CC>3 (lOmL). The aqueous fraction was extracted with DCM (2x20mL) and the combined organic fractions were dried (MgSC^) and concentrated in vacuo. The residue was purified by column chromatography to give the title compound (40.0mg, 20%) as a colourless gum. LCMS: ES+ 317.3 [MH]+.
INTERMEDIATES 92 and 93
Methyl 3-phenyl-l,2-thiazole-5-carboxylate and methyl 3-phenyl-l,2-thiazole-4- carboxylate
Figure imgf000036_0001
Benzamide (l.OOg, 8.25mmol) was dissolved in dioxane (20mL), chlorocarbonylsulfenyl chloride (0.70mL, 8.25mmol) was added and the reaction mixture was heated under reflux at 101°C for 6h. The reaction mixture was concentrated in vacuo and the residue was dissolved in m-xylene (30mL). Methyl propiolate (0.84mL, 14.0mmol) was added and the reaction mixture was heated under reflux at 139°C for 24h. The reaction mixture was concentrated in vacuo and the residue was partitioned between DCM (50mL) and water (30mL). The aqueous fraction was extracted with DCM (2x20mL) and the combined organic fractions were dried (MgSC^) and concentrated in vacuo. The residue was purified by column chromatography to give methyl 3-phenyl-l,2-thiazole-5- carboxylate (Intermediate 92, 348mg, 19%) as a yellow gum (LCMS: ES+ 220.0 [MH]+) and methyl 3 -phenyl- l,2-thiazole-4-carboxylate (Intermediate H93, 285mg, 16%) as a yellow gum (LCMS: ES+ 220.0 [MH]+).
INTERMEDIATE 94
-Phenyl-l,2-thiazole-5-carboxylic acid
Figure imgf000036_0002
Intermediate 92 (348mg, 1.59mmol) was dissolved in THF/water (lOmL, 1 :1), lithium hydroxide monohydrate (146mg, 3.49mmol) was added and the reaction mixture was stirred for 4h. The THF was removed in vacuo and the aqueous solution was acidified to pH 1 with 1M aq HCl and extracted with DCM (2x50mL). The combined organic fractions were dried (MgSC^) and concentrated in vacuo to give the title compound
(303mg, 93%) as a brown gum. LCMS: ES+ 205.9 [MH]+.
INTERMEDIATE 95
-Phenyl-l,2-thiazole-4-carboxylic acid
Figure imgf000037_0001
Intermediate 95 was prepared similarly to Intermediate 94, using Intermediate 93 instead of Intermediate 92, to give the title compound (207mg, 78%) as a brown gum. LCMS: ES+ 205.9 [MH]+.
INTERMEDIATE 96
Methyl 5-phenyl-lH-pyrazole-3-carboxylate
Figure imgf000037_0002
Methyl 2,4-dioxo-4-phenylbutanoate (470mg, 2.28mmol) was dissolved in AcOH (5mL), hydrazine hydrate (122uL, 2.51mmol) was added and the reaction mixture was heated under reflux at 118°C for 2h. The reaction mixture was concentrated in vacuo to give the title compound (320mg, 69%) as a yellow solid. LCMS: ES+ 203.0 [MH]+.
INTERMEDIATE 97
5-Phenyl- lH-pyrazole-3-carboxylic acid
Figure imgf000037_0003
Intermediate 96 (320mg, 1.58mmol) was dissolved in THF/water (15mL, 1 :1), lithium hydroxide monohydrate (146mg, 3.48mmol) was added and the reaction mixture was stirred for 2h. The THF was removed in vacuo and the aqueous solution was acidified to pH 1 with 1M aq HCl. The precipitate was collected by filtration to give the title compound (232mg, 78%) as a yellow solid. LCMS: ES+ 189.0 [MH]+. INTERMEDIATES 98-100
Intermediates 98-100 were prepared similarly to Intermediate 42, using 4- (aminomethyl)benzonitrile and the appropriate carboxylic acid; see Table 4 below.
Table 4: Amide couplings.
Figure imgf000039_0002
EXAMPLE 1
5 N- [(4-Carbamimidoylphenyl)methyl]-3-phenylbenzamide hydrochloride
Figure imgf000039_0001
Intermediate 22 (738mg, 2.37mmol) was dissolved in a solution of 14M HCl in EtOH (20mL) and stirred overnight in a sealed flask. The reaction mixture was concentrated in vacuo and a solution of 7M NH3 in MeOH (20mL) was added. The reaction mixture was 0 stirred for 44h and concentrated in vacuo to give the crude title compound (738mg). 300mg of this material was purified by mass directed HPLC. The residue was dissolved in a solution of 1.25M HCl in EtOH (5mL), stirred for 5min and concentrated in vacuo to give the title compound (113mg, 42%) as a white solid. LCMS: ES+ 330.0 [MH]+, HPLC: Rt 4.87min, 98.8%.
5
EXAMPLE 2
N-[(4-Carbamimidoylphenyl)methyl]-3-[3-(acetamidomethyl)phenyl]benzamide hydrochloride
Figure imgf000040_0001
Intermediate 52 (200mg, 0.52mmol) was dissolved in MeOH (15mL) and hydroxylamine hydrochloride (72.5mg, 1.04mmol) and DIPEA (182uL, 1.04mmol) were added. The reaction mixture was heated under reflux at 65°C for 18h. The reaction mixture was concentrated in vacuo and the residue was partitioned between water (20mL) and DCM (30mL). The aqueous fraction was extracted with DCM (3x20mL) and the combined organic fractions were concentrated in vacuo. The residue was dissolved in glacial AcOH (5mL), Ac20 (73.8uL, 0.78mmol) was added and the reaction mixture was stirred for 30min. The reaction mixture was concentrated in vacuo and the residue was dissolved in AcOH (lOmL) and hydrogenated using an H-Cube over 10% Pd/C. The reaction mixture was concentrated in vacuo and purified by reverse phase HPLC. The residue was dissolved in a solution of 4M HCl in dioxane and concentrated in vacuo to give the title compound (10.2mg, 4%) as an off-white solid. LCMS: ES+ 401.0 [MH]+, HPLC: Rt 4.19min, 98.2%. EXAMPLES 3-29 and 31-52
Examples 3-29 and 31-52 were prepared similarly to Example 1; see Table 5 below.
Table 5: Benzamidine formations
Figure imgf000041_0001
Figure imgf000042_0001
NH
2-(4-Bromophenyl)-N-[(4-
LCMS: ES+ 408.2, 410.1 [MH]
13 carbamimidoylphenyl)methyl]benzamide 26 77%
HPLC: Rt 4.81min, 98.6%. hydrochloride
Br
NH
Bis(2,2,2-trifluoroacetic acid); N-[(4-
LCMS: ES+ 331.3 [MH]
14 carbamimidoylphenyl)methyl]-2-(pyridin-3- 28 9%
HPLC: Rt 3.05min, 99.5%.
\ N ° .2TFA yl)benzamide
NH
2,2,2-Trifluoroacetic acid; N-[(4-
LCMS: ES+ 398.1 [MH]
15 carbamimidoylphenyl)methyl]-2-(3,4- 61 2%
A ° HPLC: Rt 5.05min, 97.2%.
1 J FA dichlorophenyl)benzamide
CI
NH
2,2,2-Trifluoroacetic acid; N-[(4-
LCMS: ES+ 364.2 [MH]
16 carbamimidoylphenyl)methyl]-2-(4- 62 2%
Λ HPLC: Rt 4.79min, 100%.
1 J° FA chlorophenyl)benzamide
CI
NH
2,2,2-Trifluoroacetic acid; N-[(4-
LCMS: ES+ 360.0 [MH]
17 carbamimidoylphenyl)methyl]-2-(4- 63 5%
HPLC: Rt 5.41min, 98.0%.
1 Jι ° FA methoxyphenyl)benzamide
NH
2,2,2-Trifluoroacetic acid; N-[(4-
LCMS: ES+ 377.9 [MH]
18 carbamimidoylphenyl)methyl]-4-fluoro-2-(4- 64 16%
Λ ° HPLC: Rt 4.70min, 97.7%.
1 J .TFA methoxyphenyl)benzamide
NH
Bis(2,2,2-trifluoroacetic acid); N-[(4-
LCMS: ES+ 348.9 [MH]
19 carbamimidoylphenyl)methyl]-4-fluoro-2- 65 8%
HPLC: Rt 3.20min, 100%.
1 J .2TFA (pyridin-3 -yl)benzamide
NH
2,2,2-Trifluoroacetic acid; N-[(4-
LCMS: ES+ 415.9 [MH]
20 carbamimidoylphenyl)methyl]-2-(3,4- 66 3%
Λ HPLC: Rt 5.22min, 100%.
1 J ° FA dichlorophenyl)-4-fluorobenzamide
CI
Figure imgf000045_0001
NH 2,2,2-Trifluoroacetic acid; 2-amino-N-[(4-
LCMS: ES+ 345.0 [MH]
25 carbamimidoylphenyl)methyl]-5- 70 13%
HPLC: Rt 4.76min, 98.0%.
O FA phenylbenzamide
NH 2,2,2-Trifluoroacetic acid; N-[(4-
LCMS: ES+ 344.0 [MH]
26 carbamimidoylphenyl)methyl]-2-methyl-3- 71 1%
HPLC: Rt 5.00min, 97.6%.
' O TFA phenylbenzamide
NH 2,2,2-Trifluoroacetic acid; N-[(4-
LCMS: ES+ 344.0 [MH]
27 carbamimidoylphenyl)methyl]-4-methyl-3- 72 10%
HPLC: Rt 5.20min, 98.4%.
O TFA phenylbenzamide
NH 2,2,2-Trifluoroacetic acid; N-[(4-
LCMS: ES+ 363.9 [MH]
28 carbamimidoylphenyl)methyl]-4-chloro-3- 73 1%
HPLC: Rt 5.32min, 95.1%.
O TFA phenylbenzamide
NH
N-[(4-Carbamimidoylphenyl)methyl]-2-chloro- LCMS: ES+ 363.9 [MH]
29 74 17%
3-phenylbenzamide hydrochloride HPLC: Rt 4.94min, 97.0%.
CI O .HCI
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
NH
N-[(4-Carbamimidoylphenyl)methyl]-2-{4-
LCMS: ES+ 451.0 [MH]
43 [(propan-2-yl)sulfamoyl] phenyl } benzamide 30 37%
HPLC: Rt 4.65min, 99.3%. hydrochloride
o=s=o
NH
N-[(4-Carbamimidoylphenyl)methyl]-2-[4-
LCMS: ES+ 437.0 [MH]
44 (dimethylsulfamoyl)phenyl]benzamide 31 48%
HPLC: Rt 4.74min, 98.6%. hydrochloride
o=s=o
NH
N-[(4-Carbamimidoylphenyl)methyl]-2-(3-
LCMS: ES+ 422.9 [MH]
45 methyl-4-sulfamoylphenyl)benzamide 35 48%
HPLC: Rt 4.01min, 99.6%. hydrochloride
o=s=o
NH2
Figure imgf000051_0001
Figure imgf000052_0001
EXAMPLE 54
2,2,2-Trifluoroacetic acid; N- [(4-carbamimidoylphenyl)methyl] -2-(4- methanesulfonamido phenyl)benzamide
Figure imgf000053_0001
Intermediate 27 (lOOmg, 0.31mmol) and DIPEA (O.lOmL, 0.62mmol) were dissolved in THF (2mL), methanesulfonyl chloride (26.0uL, 0.34mmol) was added and the reaction mixture was stirred for 2h. Further methanesulfonyl chloride (12.0uL, 0.16mmol) was added and the reaction mixture was stirred for lh, quenched with MeOH and concentrated in vacuo. The residue was purified by column chromatography, dissolved in sat HCl in EtOH (5mL) and stirred for 2d. The reaction mixture was concentrated in vacuo and the residue dissolved in 7M NH3 in MeOH (5mL) and stirred for 48h. The reaction mixture was concentrated in vacuo and purified by column chromatography and reverse phase HPLC. The residue was dissolved in MeOH (5mL) and TFA (ImL), stirred for lh and concentrated in vacuo to give the title compound (3.00mg, 2%) as a white solid. LCMS: ES+ 422.9 [MHf, HPLC: Rt 4.14min, 99.1%.
EXAMPLE 55
N-[(4-Carbamimidoylphenyl)methyl]-3-(3-cyanophenyl)benzamide hydrochloride
Figure imgf000053_0002
Intermediate 88 (300mg, 1.34mmol), 4-(aminomethyl)benzene-l-carboximidamide dihydrochloride (328mg, 1.48mmol) and DIPEA (585uL, 3.36mmol) were dissolved in
DMF (15mL), cooled to 0°C and PyBOP (699mg, 1.34mmol) was added. The reaction mixture was stirred at 0°C for 15min and at room temperature for 3d. The reaction mixture was concentrated in vacuo and purified by column chromatography and reverse phase HPLC. The residue was dissolved in 4M HCl in dioxane and concentrated in vacuo to give the title compound (30.1mg, 6%) as a white solid. LCMS: ES 355.3 [MH] , HPLC: Rt 4.85min, 95.8%.
EXAMPLES 57-59
Examples 57-59 were prepared similarly to Example 1; see Table 6 below.
Table 6: Benzamidine formations
Ex Structure Name Int Yield LCMS / HPLC
NH
N-[(4-Carbamimidoylphenyl)methyl]-3-phenyl- LCMS: ES+ 337.0 [MH]
57 98 2%
1 ,2-thiazole-5 -carboxamide hydrochloride HPLC: Rt 4.08min, 98.9%.
° .HCI
NH
N-[(4-Carbamimidoylphenyl)methyl]-5-phenyl- LCMS: ES+ 320.0 [MH]
58 100 2%
lH-pyrazole-3 -carboxamide dihydrochloride HPLC: Rt 4.23min, 97.9%.
° .2HCI
NH
N-[(4-Carbamimidoylphenyl)methyl]-3-phenyl- LCMS: ES+ 337.0 [MH]
59 99 52%
1 ,2-thiazole-4-carboxamide hydrochloride HPLC: Rt 4.84min, 99.2%. ί ι) ° HCI
BIOLOGICAL TESTS
PAR2 studies
The PAR2 receptor couples through the Gq signaling pathway and results in activation of calcium mobilization. The functional activity of test compounds was routinely tested by measuring the ability of compounds to antagonize PAR2 (trypsin challenge) activity in a dose dependent manner, in Wild type HEK-293 cells, 1321N1 cells transfected with the rat PAR2 receptor and 1321N1 cells transfected with the mouse PAR2 receptor, using a calcium flux Fluorescent Imaging Plate Reader FLIPR assay.
The selectivity of compounds for PAR2 versus the PARI and PAR4 receptors was evaluated using the native 1321N1 cell line. In order to confirm that activity at the PAR2 receptor was due to direct inhibition of the PAR2 receptor as opposed to inhibition of trypsin, a series of serine protease assays was developed to measure the activity of in-house compounds on enzyme activity. Functional calcium mobilisation studies
Briefly, test compounds were dissolved in DMSO to a concentration of 50mM and stored in matrix screenmate racks. The required amount of compound was transferred to 96-well compound plates on the day of assay and dose-response measurements were assayed by making 1 :3.16 serial dilutions to produce 10 point curves. Compounds were then diluted in assay buffer to the required final concentration before being transferred to 384-well assay plates ready for use. Top concentrations were adjusted depending on the potency of the compounds with a typical concentration range of 200 uM to 6.3 nM being used. The assay buffer used was HBSS buffer supplemented with 20 mM HEPES, 2.5 mM Probenicid, adjusted to pH7.4. The loading/wash buffers were the same as the assay buffer.
Wild type HEK-293 cells were cultured in MEM AQmedia containing Glutamine, supplemented with 10% FBS, 1% (5 ml) Penicillin/Streptomycin and 1% Non Essential Amino Acids. Rat or Mouse PAR2 transfected 1321N1 cells were cultured in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% dialyzed FBS, 1% Penicillin/Streptomycin, 378.5 ug/ml Geneticin G418 sulphate and maintained at 37 °C in a humidified, 5% C02 controlled atmosphere. Sub-cultivations were performed every 2-3 d. At confluence, the cells were lifted using 0.25% Trypsin (IX), spun at 1000 rpm for 3 min and re-suspended in medium at 3.3 x 105 cells/mL, transferred (30 μΐ/well) to 384-well black/clear BD plates (SLS # 56663BD) and incubated at 37 °C in a 5% C02/95% air humidified incubator for 16 h. The cells were washed with assay buffer at 37 °C using the Biotek ELx 405, washing 3 times, leaving 20 ul buffer in the well. After washing, the cells were loaded with Fluo-4 AM dye (Molecular probes) at 2 uM containing 0.48 ug/mL pluronic acid for 60 min at 37 °C under 5% C02. Following the incubation, cells were washed in assay buffer at 37 °C using the Biotek ELx 405, washing 3 times, leaving 40 μΐ in each well and incubated for 10 min at 37 °C before use.
A combined agonist/antagonist protocol was used to measure changes in intracellular calcium concentration. Compound (antagonist) was added to the cell plate using a
Fluorometric Imaging Plate Reader (FLIPR) (Molecular Devices, Sunnyvale, CA, USA).
Basal fluorescence was recorded every second for 10 sec prior to compound addition (10 uL) and fluorescence recorded every second for 1 min then every 6 sec for a further 1 min.
Trypsin (EC50 concentration) was then added using the FLIPR and fluorescense recorded as described above. Curve-fitting and parameter estimation were carried out using GraphPad
Prism 4.0 (GraphPad Software Inc., San Diego, CA).
Trypsin enzyme inhibition
The commercially available protease assay kit from Calbiochem (Cat # 539125) was used to determine inhibition of trypsin activity. The kit quantifies trypsin activity by measuring the cleaved product of FTC-casein. To measure enzyme inhibition activity, compounds were pre-incubated with trypsin before the addition of substrate. Compound IC50 was determined as percentage inhibition of trypsin. All of the exemplified compounds of the invention were found to be potent and selective inhibitors of PAR2 (See Table 7). Table 7: PAR2 antagonist activity
(A: <luM, B: 1-lOuM, C: 10-25uM)
PAR2 PAR2 PAR2 PAR2
Example Example Example Example
ICso ICso ICso ICso
1 - 17 - 33 C 49 -
2 - 18 - 34 B 50 B
3 C 19 - 35 A 51 B
4 B 20 - 36 B 52 B
5 C 21 - 37 A 54 C
6 B 22 - 38 C 55 B
7 B 23 C 39 - 57 C
8 C 24 B 40 B 58 B
9 B 25 B 41 B 59 B
10 B 26 A 42 B
11 B 27 B 43 B
12 B 28 - 44 B
13 - 29 A 45 B
14 - 31 C 46 B
15 - 32 B 47 A
16 - 48 -

Claims

1. A compound selected from:
N-[(4-Carbamimidoylphenyl)methyl]-3-phenylbenzamide hydrochloride,
N-[(4-Carbamimidoylphenyl)methyl]-3-[3-(acetamidomethyl)phenyl]benzamide, N-[(4-Carbamimidoylphenyl)methyl]-2-phenylbenzamide,
N-[(4-carbamimidoylphenyl)methyl]-3-[5-(acetamidomethyl)-2-methylphenyl]-4- methoxybenzamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(pyridin-3-yl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(lH-pyrazol-5-yl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-4-phenylpyridine-2-carboxamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(pyridin-4-yl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-5-phenylpyridine-3-carboxamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(2-methylphenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-hydroxy-5 -phenylbenzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-fluoro-5-phenylbenzamide,
2-(4-Bromophenyl)-N-[(4-carbamimidoylphenyl)methyl]benzamide,
N-[(4-carbamimidoylphenyl)methyl]-2-(pyridin-3-yl)benzamide,
N-[(4-carbamimidoylphenyl)methyl]-2-(3,4-dichlorophenyl)benzamide,
N-[(4-carbamimidoylphenyl)methyl]-2-(4-chlorophenyl)benzamide,
N-[(4-carbamimidoylphenyl)methyl]-2-(4-methoxyphenyl)benzamide,
N-[(4-carbamimidoylphenyl)methyl]-4-fluoro-2-(4-methoxyphenyl)benzamide, N-[(4-carbamimidoylphenyl)methyl]-4-fluoro-2-(pyridin-3-yl)benzamide,
N-[(4-carbamimidoylphenyl)methyl]-2-(3,4-dichlorophenyl)-4-fluorobenzamide, N-[(4-carbamimidoylphenyl)methyl]-2-(4-chlorophenyl)-4-fluorobenzamide,
1 -N- [(4-Carbamimidoylphenyl)methyl] -3 -N-(cyclopropylmethyl)-5 -phenylbenzene- 1 ,3 - dicarboxamide,
N-[(4-carbamimidoylphenyl)methyl]-2-[4-(trifluoromethyl)phenyl]benzamide, N-[(4-Carbamimidoylphenyl)methyl]-2-(4-sulfamoylphenyl)benzamide,
2-amino-N- [(4-carbamimidoylphenyl)methyl] -5 -phenylbenzamide,
N-[(4-carbamimidoylphenyl)methyl]-2-methyl-3-phenylbenzamide,
N-[(4-carbamimidoylphenyl)methyl]-4-methyl-3-phenylbenzamide,
N-[(4-carbamimidoylphenyl)methyl]-4-chloro-3-phenylbenzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-chloro-3-phenylbenzamide,
N-[(4-Carbamimidoylphenyl)methyl]-4-(4-methoxyphenyl)pyridine-3-carboxamide, N-[(4-carbamimidoylphenyl)methyl]-2-(3-methanesulfonylphenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-4-(4-sulfamoylphenyl)pyridine-3-carboxamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(4-sulfamoylphenyl)pyridine-4-carboxamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(4-sulfamoylphenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(3-sulfamoylphenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-[2-(dimethylsulfamoyl)phenyl]benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-[4-(sulfamoylamino)phenyl]benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-4-fluoro-2-(4-sulfamoylphenyl)benzamide,
4-[(3-Phenylbenzene)sulfonamidomethyl] benzene- 1-carboximidamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(l-methyl-lH-imidazol-2-yl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-[4-(methylsulfamoyl)phenyl]benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-{4-[(propan-2-yl)sulfamoyl]phenyl}benzamide, N-[(4-Carbamimidoylphenyl)methyl]-2-[4-(dimethylsulfamoyl)phenyl]benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-(3-methyl-4-sulfamoylphenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-(3-fluoro-4-sulfamoylphenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(2-methyl-4-sulfamoylphenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-(4-carbamoylphenyl)benzamide,
N-[(4-carbamimidoylphenyl)methyl]-2-(2-methyl-4-sulfamoylphenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-2-[4-(mo holine-4-sulfonyl)phenyl]benzamide,
N-[(4-Carbamimidoyl-2-chlorophenyl)methyl]-3-phenylbenzamide,
N-[(4-Carbamimidoyl-2-methylphenyl)methyl]-3-phenylbenzamide,
N-[(4-carbamimidoylphenyl)methyl]-2-(4-methanesulfonamido phenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-(3-cyanophenyl)benzamide,
N-[(4-Carbamimidoylphenyl)methyl]-3-phenyl-l,2-thiazole-5-carboxamide,
N-[(4-Carbamimidoylphenyl)methyl]-5-phenyl-lH-pyrazole-3-carboxamide
N-[(4-Carbamimidoylphenyl)methyl]-3-phenyl-l,2-thiazole-4-carboxamide,
or a pharmaceutically acceptable salt, solvate or hydrate thereof.
2. A pharmaceutical composition comprising a compound as claimed in claim 1, together with a pharmaceutically acceptable carrier.
3. The use of a compound as claimed in claim 1 in the preparation of a composition for the treatment of diseases or conditions responsive to the reduction of PAR2 mediated activity.
4. The use as claimed in claim 3 wherein the diseases or conditions are selected from inflammation including intestinal inflammation including ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome, fibrosis, arthritis and inflammatory skin diseases including psoriasis, atopic dermatitis and itch, pain and cancer.
5. A method for the treatment of diseases or conditions responsive to the reduction of PAR2 mediated activity, which comprises administering to a subject suffering such disease an effective amount of a compound as claimed in claim 1.
6. A method as claimed in claim 5 for the treatment of inflammation including intestinal inflammation including ulcerative colitis, Chrohn's disease, inflammatory bowel disease and irritable bowel syndrome, fibrosis, arthritis and inflammatory skin diseases including psoriasis, atopic dermatitis and itch, pain and cancer.
PCT/GB2013/052070 2012-08-01 2013-08-01 Receptor antagonists WO2014020351A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1213700.6A GB201213700D0 (en) 2012-08-01 2012-08-01 Receptor antagnists II
GB1213700.6 2012-08-01

Publications (1)

Publication Number Publication Date
WO2014020351A1 true WO2014020351A1 (en) 2014-02-06

Family

ID=46881510

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2013/052070 WO2014020351A1 (en) 2012-08-01 2013-08-01 Receptor antagonists
PCT/GB2013/052069 WO2014020350A1 (en) 2012-08-01 2013-08-01 Par2 receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/052069 WO2014020350A1 (en) 2012-08-01 2013-08-01 Par2 receptor antagonists

Country Status (2)

Country Link
GB (1) GB201213700D0 (en)
WO (2) WO2014020351A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10030024B2 (en) 2013-09-25 2018-07-24 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway
WO2018186365A1 (en) * 2017-04-03 2018-10-11 京都薬品工業株式会社 Read-through inducing agent and pharmaceutical application thereof
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050030T2 (en) 2015-10-02 2020-11-30 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
EP3367798A1 (en) 2015-10-28 2018-09-05 Syngenta Participations AG Microbiocidal oxadiazole derivatives
UY36999A (en) 2015-12-02 2017-06-30 Syngenta Participations Ag DERIVATIVES OF ARYL OXADIAZOL FUNGICIDAS
CN109071522B (en) 2016-04-12 2022-04-12 先正达参股股份有限公司 Microbicidal oxadiazole derivatives
UY37623A (en) 2017-03-03 2018-09-28 Syngenta Participations Ag DERIVATIVES OF OXADIAZOL THIOPHEN FUNGICIDES
CN110392683A (en) 2017-03-10 2019-10-29 先正达参股股份有限公司 Kill the oxadiazole derivatives of microorganism
WO2018177880A1 (en) 2017-03-31 2018-10-04 Syngenta Participations Ag Fungicidal compositions
MX2019011239A (en) 2017-03-31 2019-10-21 Syngenta Participations Ag Fungicidal compositions.
WO2018185013A1 (en) 2017-04-03 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018184985A1 (en) 2017-04-05 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
BR112019020819B1 (en) 2017-04-05 2023-12-05 Syngenta Participations Ag COMPOUND OF FORMULA (I), AGROCHEMICAL COMPOSITION, METHOD FOR CONTROLLING OR PREVENTING INFESTATION OF USEFUL PLANTS BY PHYTOPATHOGENIC MICROORGANISMS AND USE OF A COMPOUND OF FORMULA (I)
BR112019021019B1 (en) 2017-04-05 2023-12-05 Syngenta Participations Ag Microbiocidal oxadiazole-derived compounds, agricultural composition, method for controlling or preventing infestation of useful plants by phytopathogenic microorganisms and use of an oxadiazole-derived compound
WO2018184986A1 (en) 2017-04-05 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018184984A1 (en) 2017-04-05 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018184982A1 (en) 2017-04-05 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018185211A1 (en) 2017-04-06 2018-10-11 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US11447481B2 (en) 2017-06-02 2022-09-20 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2019011928A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2019011926A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
BR112020000465B1 (en) 2017-07-11 2024-02-20 Syngenta Participations Ag OXADIAZOLE DERIVATIVES MICROBIOCIDES
WO2019011929A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
BR112020000414A2 (en) 2017-07-12 2020-07-21 Syngenta Participations Ag microbicidal oxadiazole derivatives
BR112020000371A2 (en) 2017-07-12 2020-07-14 Syngenta Participations Ag microbiocidal oxadiazole derivatives
BR112020000463A2 (en) 2017-07-13 2020-07-21 Syngenta Participations Ag microbiocidal oxadiazole derivatives
WO2019097054A1 (en) 2017-11-20 2019-05-23 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
BR112020021645A2 (en) 2018-04-26 2021-01-26 Syngenta Participations Ag microbicidal oxadiazole derivatives
CN112689631A (en) 2018-07-16 2021-04-20 先正达农作物保护股份公司 Microbicidal oxadiazole derivatives
KR20220058530A (en) * 2019-07-08 2022-05-09 레졸루트 인크 Method for the preparation of plasma kallikrein inhibitors
EP3831940A1 (en) * 2019-12-05 2021-06-09 Danmarks Tekniske Universitet Small molecule inhibitors of crispr-cas associated activity
KR20230048439A (en) 2020-08-18 2023-04-11 세파론 엘엘씨 Anti-PAR-2 Antibodies and Methods of Using The Same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139401A9 (en) * 2000-11-20 2003-07-24 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US20050137168A1 (en) * 2003-12-19 2005-06-23 Gobbi Luca C. Heterocyclyl substituted 1-alkoxy acetic acid amides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139401A9 (en) * 2000-11-20 2003-07-24 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US20050137168A1 (en) * 2003-12-19 2005-06-23 Gobbi Luca C. Heterocyclyl substituted 1-alkoxy acetic acid amides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10030024B2 (en) 2013-09-25 2018-07-24 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway
WO2018186365A1 (en) * 2017-04-03 2018-10-11 京都薬品工業株式会社 Read-through inducing agent and pharmaceutical application thereof
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Also Published As

Publication number Publication date
GB201213700D0 (en) 2012-09-12
WO2014020350A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
WO2014020351A1 (en) Receptor antagonists
AU2002247367B2 (en) Aryl and biaryl compounds having MCH modulatory activity
EP2607348B1 (en) Plasminogen Activator Inhibitor-1 Inhibitor
NO328599B1 (en) Orthosubstituted and metasubstituted bisaryl compounds, their use as a drug, pharmaceutical compositions containing the compounds, and their use in the manufacture of medicaments
PL198032B1 (en) Derivatives of amides, method of obtaining them and pharmaceutic compositions containing such derivatives
JP2005505515A (en) Arylamines for the treatment of conditions associated with GSK-3
WO2006027680A1 (en) 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
EP2668157A1 (en) Protease activated receptor 2 (par2) antagonists
US6737425B1 (en) N,N-substituted cyclic amine derivatives
US8859605B2 (en) Cysteine protease inhibitors
US9862678B2 (en) 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death
JP5666468B2 (en) Cysteine protease inhibitor
US7317025B2 (en) Non-peptidic NPY Y2 receptor inhibitors
AU2014214325A1 (en) Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
WO2017123826A1 (en) Mast-cell modulators and uses thereof
US6544982B1 (en) Thrombin receptor antagonists
EP2582660B1 (en) New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions
JP2015516969A (en) Substituted 4-aminobenzamide as a KCNQ2 / 3 regulator
WO2012168852A1 (en) Cysteine protease inhibitors
CZ20003868A3 (en) Amides and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13747687

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13747687

Country of ref document: EP

Kind code of ref document: A1